Clinical Trial Update: Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder [Phase 2]

View source ↗

Summary

Phase 2 study of a cisplatin, gemcitabine, and sorafenib combination for bladder cancer; no results or current status are reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• Sorafenib tosylate (sorafenib tosylate)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Bladder Cancer | Phase 2 | Status: UNKNOWN